Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04931459 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
A Phase 1 study, sponsored by Acumen Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT04931459 is a Phase 1 study that has completed, run by Acumen Pharmaceuticals. The registered enrollment target is 65 participants.
The verdict
NCT04931459, a Phase 1 study, has completed, sponsored by Acumen Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when administered to participants diagnosed with Mild Cognitive Impairment (MCI) or Mild Dementia due to Alzheimer's disease (AD).
Interventions
- DRUG Placebo
- DRUG ACU193
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2021-06-21 |
| Est. Completion | 2023-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04931459
The ClinicalTrials.gov registry entry for NCT04931459 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acumen Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04931459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04931459 about?
NCT04931459 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD". This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when administered to participants diagnosed with Mild Cognitive Impairment (MCI...
What is the current status of trial NCT04931459?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2021-06-21. Estimated completion is 2023-06-12.
What interventions are being tested in trial NCT04931459?
The interventions under investigation include: Placebo (DRUG), ACU193 (DRUG).
Who is sponsoring clinical trial NCT04931459?
This trial is sponsored by Acumen Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.